Tiziana Life Sciences Ltd (TLSA) Stock Score, Valuation & Financial Research

Tiziana Life Sciences Ltd is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TLSA

Tiziana Life Sciences Ltd does not currently have a complete Wall Street Score. The stored market price is USD 1.11. These figures are a research snapshot, not a buy or sell recommendation.

What Tiziana Life Sciences Ltd does

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Tiziana Life Sciences is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research and development of proprietary immunotherapies, specifically nasal delivery technologies for neurodegenerative diseases.

Products and services

  • The company is developing Foralumab, a fully human anti-CD3 monoclonal antibody, as a nasal immunotherapy for conditions including secondary progressive multiple sclerosis, Alzheimer's disease, and ALS. It also holds assets related to TZLS-501, an anti-IL-6 receptor monoclonal antibody.

Brands and product families

  • Foralumab — Lead clinical-stage drug candidate for nasal immunotherapy. Source
  • TZLS-501 — Anti-IL-6 receptor monoclonal antibody asset. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct clinical trials and manage development activities. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturing organizations for the production of clinical trial materials. Source

Business relationships and partnerships

  • Novimmune SA — The company entered into a worldwide license agreement with Novimmune SA for the composition-of-matter of TZLS-501 and the in-licensing of the Foralumab molecule. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various established and emerging biopharmaceutical companies developing therapies for multiple sclerosis, Alzheimer's, and other neurodegenerative diseases. Source

Business strengths to evaluate

  • Proprietary nasal delivery technology platform Source
  • Clinical development of Foralumab Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Dependence on third-party manufacturers and clinical research organizations Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source · Novimmune SA

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TLSA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.11
Market capitalization:
70.63M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -34.95M
Free cash flow:
USD -12.87M
Cash:
USD 4.01M
Total debt:
USD 456K
EPS:
USD -0.63

What stands out

  • Free cash flow is USD -12.87M, negative for the stored period.
  • The balance sheet shows USD 4.01M of cash versus USD 456K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 3.55M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TLSA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TLSA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TLSA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TLSA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of TLSA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TLSA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.